Vector VestAdvertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

OPK RSS Feed
Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator stonsetr, Myth, now invest, ntropy
Search This Board:
Last Post: 1/28/2015 12:36:33 AM - Followers: 125 - Board type: Free - Posts Today: 2
Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OPK
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for OPK
OPK News: Statement of Changes in Beneficial Ownership (4) 01/26/2015 09:29:05 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 01/23/2015 09:28:38 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 01/22/2015 07:46:33 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 01/21/2015 09:26:45 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 01/20/2015 07:11:20 AM
PostSubject
#3215  Sticky Note Pfizer Partners With Young Little Known Biotech For tomsylver 12/18/14 09:06:21 AM
#2454  Sticky Note May 9, 2014, 10:17am EDT Myth 06/03/14 02:38:24 PM
#3303   That after hour pump though. That average isn't md84 01/28/15 12:36:33 AM
#3302   You guys must be new here. md84 01/28/15 12:34:39 AM
#3301   It could that again but I don't think game7alcs 01/27/15 09:30:10 PM
#3300   Anyone hear of a pull back? Lol nothing Sone 01/27/15 08:52:12 PM
#3299   Wow $20 - $30 in couple months,, LoL Gingi 01/27/15 08:14:33 PM
#3298   I would like it to but I don't game7alcs 01/27/15 05:15:43 PM
#3297   I hope you're joking, because I was not. md84 01/27/15 04:36:16 PM
#3296   You will never see 20-30 in a couple game7alcs 01/27/15 03:54:09 PM
#3295   Some selling is healthy. Weeds out the day md84 01/27/15 03:31:59 PM
#3294   Not that it matters but I completely disagree game7alcs 01/27/15 11:20:39 AM
#3293   It's trying to push through game7alcs 01/27/15 11:16:37 AM
#3292   That was my Twitter question btw :) Blown Income 01/27/15 10:03:44 AM
#3291   Cramer Answers Twitter Questions, opko health ?Video Link ( tomsylver 01/27/15 12:59:14 AM
#3290   I think you're chances a very good to game7alcs 01/26/15 10:44:17 PM
#3289   I have sold a few so far... but now invest 01/26/15 10:16:20 PM
#3288   Good luck to you! Most if my shares game7alcs 01/26/15 09:18:09 PM
#3287   Nice HOD close at $11.38 ntropy 01/26/15 04:01:56 PM
#3286   Well.. most stocks try to do that.. and now invest 01/26/15 03:29:14 PM
#3285   So you think we go to the resistance game7alcs 01/26/15 03:18:08 PM
#3284   AN NEW HIGH... 11.27 !!!! now invest 01/26/15 02:35:40 PM
#3283   All of the shorts must be running to ntropy 01/26/15 12:03:45 PM
#3282   Opko's 4Kscore in the long run will prove tomsylver 01/26/15 01:46:07 AM
#3281   SciGen, SCI-B-VAC tomsylver 01/26/15 01:10:36 AM
#3280   Yea as long as they can get the game7alcs 01/25/15 11:25:34 PM
#3279   Totally within my realm of predictions Teva or Gingi 01/25/15 10:05:37 PM
#3278   I completely agree with you. I think OPK game7alcs 01/25/15 09:11:53 PM
#3277   Great post... i agree! ntropy 01/25/15 07:57:25 PM
#3276   Not sure whether Geopolitical conditions have much impact Gingi 01/25/15 12:32:53 PM
#3275   World's events aren't going to help the market game7alcs 01/24/15 03:45:56 PM
#3274   Opk's next resistance is in the 11.55 range... now invest 01/24/15 02:59:06 PM
#3273   Maybe we push through $11 next week game7alcs 01/24/15 10:38:34 AM
#3272   10.99 new high!! now invest 01/24/15 10:04:42 AM
#3271   $10.91 - New 52 week high ;) ntropy 01/23/15 11:28:23 AM
#3270   Yep... he knows what he's doing & if ntropy 01/23/15 11:26:48 AM
#3269   Frost just keeps buying. stonsetr 01/23/15 10:06:45 AM
#3268   The 52 week high was hit today... $10.62. ntropy 01/22/15 04:42:13 PM
#3267   Frost is a genius in many respects, as ntropy 01/22/15 04:33:08 PM
#3266   They all lost their shorts :) ntropy 01/22/15 04:13:31 PM
#3265   Smart money! :) ntropy 01/22/15 04:12:25 PM
#3264   There are still some out there. Brrrrave souls! stonsetr 01/22/15 03:14:40 PM
#3263   We're all the shorts go? ;-) Sone 01/22/15 02:32:03 PM
#3262   The National Prostate Cancer Plan Act Introduced By tomsylver 01/22/15 08:04:08 AM
#3261   Frost still buying in this rotten market... now invest 01/20/15 10:51:56 AM
#3260   Looks like an epic battle to protect 10 nolossray 01/16/15 02:23:18 PM
#3259   Looked at the Presentation.. I see money now invest 01/14/15 12:47:25 PM
#3258   New Form 8-K/Current Report out http://investor.opko.com/secfiling.cfm?filingid tomsylver 01/14/15 08:01:04 AM
#3257   It was a good presentation. Nothing earth shattering game7alcs 01/13/15 07:29:25 PM
#3256   Great clip! game7alcs 01/13/15 04:14:26 PM
#3255   Dr. Harry Fisch Show Opko 4Kscore Test for tomsylver 01/13/15 02:53:43 PM
#3254   Why is this dropping on such great PR? TradePoet 01/13/15 02:18:00 PM
PostSubject